NCT06522568 Testing a Mammography Decision Intervention in a Rural Setting
| NCT ID | NCT06522568 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 39 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 39 participants in total. It began in 2025-09-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.
Eligibility Criteria
Patient Inclusion Criteria: * Females * Aged 39-49 * Upcoming appointment with a participating primary care provider (within 4 weeks) * English or Spanish-speaking Patient Exclusion Criteria: * Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia) * Mammogram in the prior 12 months Clinician inclusion: Any practicing primary care provider at a participating site.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06522568 clinical trial?
This trial is open to female participants only, aged 39 Years or older, up to 49 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06522568 currently recruiting?
Yes, NCT06522568 is actively recruiting participants. Contact the research team at Christine.M.Gunn@dartmouth.edu for enrollment information.
Where is the NCT06522568 trial being conducted?
This trial is being conducted at Keene, United States.
Who is sponsoring the NCT06522568 clinical trial?
NCT06522568 is sponsored by Dartmouth-Hitchcock Medical Center. The trial plans to enroll 39 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.